Supplementary Figure 1: Metabolic gene mutation accumulation in metastatic tumors
A. Bar graphs showing frequency of tumors bearing single or multiple mutations in genes belonging to different metabolic categories in the pan-cancer dataset. B-F. Kaplan-Meir survival curves for pan-cancer tumors stratified according to cumulative frequencies of single or multiple mutations or no mutations in the metabolic gene category. P-values indicate significance levels from the comparison of survival curves using the log-rank (Mantel-Cox) test). G. Comparison between primary and metastatic tumors for frequency of tumors with mutations in individual metabolic genes. Red bars indicate the frequency of tumors with a non-synonymous mutation, grey bars indicate -log10 of the p-value from Fischer's exact test (two-tailed) comparing mutation frequency of a gene between primary and metastatic tumors. Inset bar graph shows basal mutation frequency of all genes in the total pan-cancer dataset and primary or metastatic tumors. H. Bars indicating the percentage of genes within each metabolic gene category with significantly altered mutation frequency between primary and metastatic tumor. Red bars indicate percentage of significant mutations, and grey bars indicate non-significant genes. The percentage of significant genes in the REACTOME carbohydrate metabolism and lipid metabolism gene sets are shown for comparison.
Supplementary Figure 3: EMT score correlation heatmap
Heatmap indicating the Pearson's correlation coefficient of the different metabolic genes (Y-axis) with EMT score within a given cancer type (X-axis). Red indicates high magnitude of positive correlation, grey indicates negative correlation and white indicates low correlation. Horizontal blue boxes indicate patterns that are consistent across all cancer types, including positive correlation between CAV1 and CD36 with EMT scores, and negative correlation between DGAT1 and DGAT2 with EMT scores. Vertical blue boxes indicate patterns of a metabolic gene category consistent in a given cancer type, including negative correlation between genes in the FA oxidation and lipogenesis category with EMT score in lung cancer and negative correlation between Warburg effect genes and EMT score in ovarian cancer.
Supplementary Figure 4: Summary of alterations in metastatic tumors
Metabolic pathway model modified to indicate the genes that were identified as significantly altered in metastatic tumors with significant impact on patient prognosis. The red-highlighted ovals show genes with metastasis-associated gain-of-function alterations with prognostic significance. The bluehighlighted ovals show the genes with loss-of-function alterations with prognostic significance in cancer but did not differ between primary and metastatic samples.
Supplementary Figure 5: Copy number and survival
Survival curves genes with significantly higher copy numbers in metastatic tumors in the pancancer dataset. P-values indicate significance levels from the comparison of survival curves using the log-rank (Mantel-Cox) test.
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